Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 28, 2019

Serum omentin-1 levels in obese children

Senay Zengi, Oguzhan Zengi, Aysegul Kirankaya, Suat Hayri Kucuk, Emine Erdogan Kutanis and Ozgul Yigit



Obesity is an important cause of morbidity, and it has an increasing frequency in childhood. Studies have reported that 33% of adults and 20–27% of children and adolescents are obese. Recently, it has been shown that the prevalence of obesity in the childhood group is higher than the past years. Omentin-1 is an adipokine which is synthesized from the visceral fat tissue but not synthesized in the subcutaneous fat tissue. Omentin-1 has been shown to increase insulin-mediated glucose uptake, especially in the adipose tissue. Studies have shown that plasma omentin-1 levels, which play an important role in the pathogenesis of insulin resistance, are significantly lowered in obese, polycystic ovary syndrome (PCOS) and diabetic patients. The aim of this study was to investigate the relationship between obesity and omentin-1 levels in children.


The study included obese children with a body mass index (BMI) greater than the 95th percentile and healthy children with a BMI lower than the 85th percentile. Obese and healthy individuals had similar age and sex distributions. Glucose, insulin, lipid profiles, thyroid panels and metabolic markers were evaluated.


The levels of omentin-1 in obese children were significantly lower than in the control group (p<0.05). Results of Spearman’s correlation analysis for all participants showed that omentin-1 levels were negatively related with triglycerides, total cholesterol, serum free thyroxine (FT4), insulin, homeostatic model assessment of insulin resistance (HOMA-IR), body weight, waist circumference (WC) and BMI percentile values.


Our findings indicate that serum omentin-1 levels are lower in obese children than in non-obese individuals. Omentin-1 can be used as a metabolic biomarker in children and adolescents.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Catli G, Anik A, Abaci A, Kume T, Bober E. Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Exp Clin Endocrinol Diabetes 2013;24085389.10.1055/s-0033-1355338Search in Google Scholar PubMed

2. Jamurtas AZ, Stavropoulos-Kalinoglou A, Koutsias S, Koutedakis Y, Fatouros I. Adiponectin, resistin, and visfatin in childhood obesity and exercise. Pediatr Exerc Sci 2015;27:454–62.10.1123/pes.2014-0072Search in Google Scholar PubMed

3. Barraco GM, Luciano R, Semeraro M, Prieto-Hontoria PL, Manco M. Recently discovered adipokines and cardio-metabolic comorbidities in childhood obesity. Int J Mol Sci 2014;15:19760–76.10.3390/ijms151119760Search in Google Scholar PubMed PubMed Central

4. Kotnik P, Fischer Posovszky P, Wabitsch M. Endocrine and metabolic effects of adipose tissue in children and adolescents. Zdr Varst 2015;54:131–8.Search in Google Scholar

5. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29–33.10.1016/j.diabres.2010.01.013Search in Google Scholar PubMed

6. Nurten E, Vogel M, Michael Kapellen T, Richter S, Garten A, et al. Omentin-1 and NAMPT serum concentrations are higher and CK-18 levels are lower in children and adolescents with type 1 diabetes when compared to healthy age, sex and BMI matched controls. J Pediatr Endocrinol Metab 2018;31:959–69.10.1515/jpem-2018-0353Search in Google Scholar PubMed

7. Koyuncuo N. Overweight and obesity in children and adolescents. J Clin Res Pediatr Endocrinol 2014;6:129–43.Search in Google Scholar

8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.10.1007/BF00280883Search in Google Scholar PubMed

9. Zehsaz F, Farhangi N, Ghahramani M. The response of circulating omentin-1 concentration to 16-week exercise training in male children with obesity. Phys Sportsmed 2016;44:355–61.10.1080/00913847.2016.1248223Search in Google Scholar PubMed

10. Prats-Puig A, Bassols J, Bargalló E, Mas-Parareda M, Ribot R, et al. Toward an early marker of metabolic dysfunction: omentin-1 in prepubertal children. Obesity 2011;19:1905–7.10.1038/oby.2011.198Search in Google Scholar PubMed

11. Batista CM, Yang R, Lee M, Glynn NM, Yu D, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655–61.10.2337/db06-1506Search in Google Scholar PubMed

12. Yang R-Z. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. AJP Endocrinol Metab 2006;290:E1253–61.10.1152/ajpendo.00572.2004Search in Google Scholar PubMed

13. Zhou J-Y, Chan L, Zhou S. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014;12:136–43.10.2174/1570161112999140217095038Search in Google Scholar PubMed

14. Ng AC, Wai DC, Tai ES, Ng KM, Chan LL. Visceral adipose tissue, but not waist circumference is a better measure of metabolic risk in Singaporean, Chinese and Indian men. Nutr Diabetes 2012;2:e38.10.1038/nutd.2012.12Search in Google Scholar PubMed PubMed Central

Received: 2018-05-31
Accepted: 2019-01-01
Published Online: 2019-02-28
Published in Print: 2019-03-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow